FT819-102
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate-to-severe active systemic lupus…
- Investigator
- Michael R Bubb
- Status
- Accepting Candidates
- Ages
- 12 Years - 70 Years
- Sexes
- All
CABA-201 for SLE
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Investigator
- Michael R Bubb
- Status
- Accepting Candidates
- Ages
- 18 Years - 65 Years
- Sexes
- All
NKARTA NKX019-102
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune…
- Investigator
- Michael R Bubb
- Status
- Accepting Candidates
- Ages
- 18 Years - 75 Years
- Sexes
- All